EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis
EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis. // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1533002826000691?dgcid=rss_sd_all
EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis. Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S1533002826000691?dgcid=rss_sd_all
“EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis.” Clinical Colorectal Cancer.
@article{article40535,
title = {EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1533002826000691?dgcid=rss_sd_all}
}